spacer
home > ebr > Spring 2003
PUBLICATIONS

European Biopharmaceutical Review

ebr
Spring 2003
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR.
   
Text
PDF
In her Editor's Letter, Dr Helen Abbott gives us a brief synopsis of the range and content of this issue  
view
bullet
STRATEGY AND FINANCE
Neal Ransome, Partner at PricewaterhouseCoopers, examines how Capital Markets Slowdown Triggers Pharma Micro-Deals in 2002  
view
Inadequate publicity and financing can hold biotech companies back. Biotech Companies in the Pharma Market - Grow or be Doomed, warns Dr Volker Janssen, Director at Simon-Kucher & Partners  
view
In Partners With Vision - A Discussion on the Future of Pharma, William Powlett Smith, Audit Partner and Leader of UK Health Sciences at Ernst & Young, explores the importance of a long-range vision to pharmaceutical industry development  
view
Dr Peter Seufer-Wasserthal, Vice President of Business Development at Morphochem AG, takes us From Platform to Product - Delivering the Pipelines of Tomorrow  
view
Science and Innovation
Kelvin Stott and Andrew J Doig at Senexis Limited, explore the potential of Meptides: A Novel Class of Synthetic Peptide Derivatives for the Potential Treatment of Neurodegenerative Diseases  
view
Mass spectrometry is widely viewed as the preferred analytical technique in proteomics research. Dr Chris Sutton, Global Business Manager with Kratos Analytical, considers its popularity, in MALDI-TOF - The Technique of Choice in Proteomics  
view
Drug discovery requires millions of parallel biological tests on a miniature scale. In Catching the Code, Dr Ciaran Sewter, Dr Mark Evans and Dr Elizabeth Hill at 3D Molecular Sciences Ltd, suggest one possible approach  
view
bullet
Legal, Regulatory and Public Policy
G Steven Burrill, CEO of Burrill & Company, examines the trend of pharmacogenomic testing, in From Pipe Dream to Pipeline Dream: Personalised Medicine Takes Off  
view
In conversation with biotechnology reporter Allison Connolly, Dr Jeffrey Ross of Millennium Pharmaceuticals discusses Molecular Medicine: Targeting Patients with the Right Treatment  
view
Inhalation is an effective but potentially hazardous method of drug delivery. Dr Colin J Hardy, Director of Inhalation Studies at Huntingdon Life Sciences investigates, in Assessing the Safety of Inhaled Biopharmaceuticals - Current Issues and Recent Developments  
view
Sonja Lenz, Klaus Kellings and Helga Siakkou at NewLab BioQuality AG, look at Variant Creutzfeldt-Jakob Disease: Safety of Blood and Plasma Products  
view
bullet
PATENTING POLICY AND PRACTICE
In Bioprospecting: Beyond Intellectual Property Rights - the Indigenous Challenge, Hayley French and Helen Cline at Taylor Wessing, discuss the issue of collecting biological samples  
view
Dr Armin Bohmann, Founder and Partner of Bohmann & Loosen, and Dr Ulrich Gerth, Vice President of Equity Corporate Finance at Hypovereinsbank Corporates & Markets, highlight The Importance of Provisional Protection for Biotech Inventions  
view
Brian Cain, Solicitor with Richards Butler, considers recent developments in the area of Utility, Inventiveness and Patenting DNA  
view
In the concluding part of our two-part series, Absolute or Limited Product Protection for Biotech Inventions, Dr Uta Koster, Associate with Bardehle Pagenberg, analyses the various national laws and regulations within the EC and US  
view
bullet
Regional Focus: Scandinavia
The advantages of the Medicon Valley biotech cluster are outlined in Biotech's Northern Alliance Gaining Ground: a report by Hal Grey, freelance journalist writing for Position SkЊne and Copenhagen Capacity  
view
bullet
CANCER FOCUS
Dr Frank E Jones, Dr Matthew E Burow and Dr Steven M Hill of Tulane Cancer Center discuss Signal Transduction in Breast Cancer: Silencing the Cross-Talk  
view
In The Development of PARP Inhibitors to Treat Cancer and Other Diseases, Professor Stephen P Jackson, Founder of KuDOS Pharmaceuticals Ltd, investigates the use of enzymes for DNA damage detection, signalling and repair  
view
Dr Ramachandran Murali, Assistant Professor in the Department of Pathology and Laboratory of Medicine at the University of Pennsylvania, describes SPR Analysis of Rationally Designed Anti-HER2 Exocyclic Mimetics of Antibodies  
view
bullet
APPLIED RESEARCH, DEVELOPMENT AND PRODUCTION
In Large-Scale, Comprehensive Quality Control and Analysis of High-Throughput Screening Data, Swen Reimann, Michael Lindemann, Bernd Rinn, Olivier Lefèvre and Stephan Heyse at GeneData AG, suggest ways to get the most from HTS  
view
Dr Jens Beator of Schleicher & Schuell BioScience, outlines approaches for proteome research, in From Protein Microarrays to Cytokine Detection Chips  
view
Dr Richard Philpott, Managing Director of Acumen Bioscience Ltd, introduces Live Cells as Drug Discovery Tools - High-Throughput, High-Content Screening  
view
Dr Robert Jones at Cambridge Consultants discusses the advantages and limitations of Surface Plasmon Resonance Applied to the High-Throughput Measurement of Molecular Binding  
view
In Robotics in Pharmaceutical Research, David N Sands, CEO and Founder of ST Robotics International, describes some of the applications for the pharmaceutical industry  
view
Dr Morten Bryhn, Director of R&D at Pronova Biocare, demonstrates the value of Omega-3 Fatty Acids in the Prevention of Myocardial Infarction  
view
Gareth Davies, Operations Director at CEL International, highlights issues to be considered to get the best performance from a "fast track" project, in Fast Track Project Implementation: Risk or Reward?  
view
bullet
REGIONAL FOCUS: CENTRAL EUROPE
What is biosaxony and how does it differ from the many other bio-locations? Dr Ivan Baines, Partner at Biopolis Consultants, introduces us to The biosaxony Region  
view
In The Meuse-Rhine Triangle, Stafford Wadsworth, Editor and Publisher of the Meuse-Rhine Journal, explores the potential of this fast-growing Euroregion  
view
bullet
REGIONAL FOCUS: NORTH CAROLINA
In Where to Biomanufacture? One State's Efforts to Answer the Question, Barry D Teater, Director of Corporate Communications at the North Carolina Biotechnology Center, discusses biomanufacturing opportunities in North Carolina  
view
bullet
REVIEWS AND PREVIEWS
Dr Keith Chidwick, Consultant at Technomark Consulting Services, reports from the recent Biotech Manufacturing 2003 conference in Amsterdam  
view
CORDIA - EuropaBio* Convention 2003 is Europe's brand new life science convention. Launching in Vienna at the end of 2003, CORDIA is not simply a conference, nor is it purely an exhibition; its sole purpose is to provide a platform to stimulate the growth of the European biotechnology industry.  
view
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

Avacta and Mologic Enter Research and Product Development Collaboration Agreement

Avacta announces the formation of a collaborative research partnership
More info >>

White Papers

The Promise and Challenge of Adaptive Design in Oncology Trials

Medpace

Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research. Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
More info >>

Industry Events

Pharma and Device Packaging and Labeling West Coast 2017

28-29 November 2017, Burlingame, California

Following a very successful launch year, we are thrilled to announce that Pharma and Device Packaging and Labeling will be returning to the West Coast for our 2nd annual event.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement